Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

PHASE3CompletedINTERVENTIONAL
Enrollment

780

Participants

Timeline

Start Date

January 31, 1998

Primary Completion Date

November 30, 2001

Conditions
Sarcoma
Interventions
DRUG

doxorubicin hydrochloride

DRUG

ifosfamide

Trial Locations (23)

1125

National Institute of Oncology, Budapest

2100

Rigshospitalet, Copenhagen

69373

Centre Leon Berard, Lyon

B-2650

Universitair Ziekenhuis Antwerpen, Edegem

B-3000

U.Z. Gasthuisberg, Leuven

DK-8000

Aarhus Kommunehospital, Aarhus

F-94805

Institut Gustave Roussy, Villejuif

D-30625

Medizinische Hochschule Hannover, Hanover

D-81377

Klinikum Grosshadern, Munich

1066 CX

Antoni van Leeuwenhoekhuis, Amsterdam

2300 CA

Leiden University Medical Center, Leiden

NL-6252 HB

University Medical Center Nijmegen, Nijmegen

3075 EA

Rotterdam Cancer Institute, Rotterdam

02-781

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw

833 10

National Cancer Institute - Bratislava, Bratislava

G.C.

Hospital Insular de Gran Canaria, Las Palmas

LS9 7TF

St. James's Hospital, Leeds

SW3 6JJ

Royal Marsden NHS Trust, London

WIT 3AA

Middlesex Hospital- Meyerstein Institute, London

M20 4BX

Christie Hospital N.H.S. Trust, Manchester

NE4 6BE

Newcastle General Hospital, Newcastle upon Tyne

NG5 1PB

Nottingham City Hospital NHS Trust, Nottingham

S1O 2SJ

Weston Park Hospital, Sheffield

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00003212 - Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter